DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

03681 SINOMAB BIO-B

Trading Add to Porfolio
Index Constituent : None
Major Shareholders Hainan Haiyao Co., Ltd. (11.46%)
Shui On LEUNG (9.36%)
Wenyi LIU & Associates (8.88%)
Xu Sijia (5.94%)		 Sector Health Care & Biotechnology
Web Site http://www.sinomab.com Tel (852) 3426-9833
Email message@sinomab.com Fax N/A
Related Equities N/A
Principal Activities Principally involved in the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (“mAb”)-based biologics.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top